Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia

Lidong Jiao,1 Xiaoqin Huang,1 Chunqiu Fan,1 Hong Zhao,2 Zhen Li,3 Huixin Shen,1 Jian Chen,4 Jiangang Duan5 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Hematology, Xuanwu Hospital, Capital Medical University, Bei...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Jiao L, Huang X, Fan C, Zhao H, Li Z, Shen H, Chen J, Duan J
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2021
Materias:	cerebral venous thrombosis jak2 v617f anticoagulant therapy cytoreductive ther-apy essential thrombocythemia. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
Acceso en línea:	https://doaj.org/article/d02231c1052e42b097b0a9fe655961c7
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:d02231c1052e42b097b0a9fe655961c7
record_format	dspace
spelling	oai:doaj.org-article:d02231c1052e42b097b0a9fe655961c72021-12-02T17:32:12ZClinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia1178-2021https://doaj.org/article/d02231c1052e42b097b0a9fe655961c72021-04-01T00:00:00Zhttps://www.dovepress.com/clinical-characteristics-and-management-of-cerebral-venous-sinus-throm-peer-reviewed-fulltext-article-NDThttps://doaj.org/toc/1178-2021Lidong Jiao,1 Xiaoqin Huang,1 Chunqiu Fan,1 Hong Zhao,2 Zhen Li,3 Huixin Shen,1 Jian Chen,4 Jiangang Duan5 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Department of Ophthalmology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China; 4Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China; 5Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Xiaoqin HuangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People’s Republic of ChinaTel +86 10-83198899– 8319Email huangxqxw@126.comBackground and Objective: Essential thrombocythemia (ET) is a rare cause of cerebral venous sinus thrombosis (CVST). Analysis of the risk factors and treatment therapies of CVST in ET has yielded controversial findings.Subjects and Methods: We retrospectively investigated the clinical characteristics of CVST events in ET and compared baseline characteristics, causative factors, hematological effects, and treatments between ET patients with and without CVST.Results: Overall, 91 of 115 patients who met the ET diagnosis were included in this study. Among them, 23 (25.27%) patients met the diagnostic criteria of ET with CVST for inclusion, 14 (60.87%) of whom were females, with a median age of 34 (range 25– 50). CVST diagnosis was made concomitantly to ET in 19 patients (82.61%). The most common symptom and sites of thrombosis of CVST was an acute or subacute headache and sigmoid sinuses, respectively. Compared with ET patients without CVST, ET patients with CVST were significantly younger (37.65± 14.45 vs 60.93± 13.46, P< 0.001) and had lower prevalence of hypertension (4.34 vs 32.35%, P=0.003) and coronary artery disease (0 vs 14.71%, P = 0.045). Patients with CVST presented with signiﬁcant lower platelet count (510.39± 176.71 vs 750.82± 249.10, P< 0.001) and higher score of IPSET-thrombosis (P=0.017). Multivariate logistic regression analysis indicated that age (P=0.002, OR 1.096, 95% CI 1.035– 1.161), at least one CVRF (P = 0.024, OR 0.037, 95% CI 0.002– 0.649), platelet count (P=0.045, OR 0.994, 95% CI 0.989– 1.001), and lower percentage of antiplatelet therapy (P=0.035, OR 0.307, 95% CI 0.001-1.280) significantly contributed to the risk of CVST in ET.Conclusion: Most patients (95.65%) had a favorable outcome without recurrence after standard anticoagulant and cytoreductive treatment at last follow-up. These findings indicate that CVST may be the initial presentation of ET, with its detection crucial for early diagnosis and appropriate management. Anticoagulant and cytoreductive therapies should be recommended for preventing ET-related CVST with JAK2 V617F mutation.Keywords: cerebral venous thrombosis, JAK2 V617F, anticoagulant therapy, cytoreductive therapy, essential thrombocythemiaJiao LHuang XFan CZhao HLi ZShen HChen JDuan JDove Medical Pressarticlecerebral venous thrombosisjak2 v617fanticoagulant therapycytoreductive ther-apyessential thrombocythemia.Neurosciences. Biological psychiatry. NeuropsychiatryRC321-571Neurology. Diseases of the nervous systemRC346-429ENNeuropsychiatric Disease and Treatment, Vol Volume 17, Pp 1195-1206 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cerebral venous thrombosis jak2 v617f anticoagulant therapy cytoreductive ther-apy essential thrombocythemia. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429
spellingShingle	cerebral venous thrombosis jak2 v617f anticoagulant therapy cytoreductive ther-apy essential thrombocythemia. Neurosciences. Biological psychiatry. Neuropsychiatry RC321-571 Neurology. Diseases of the nervous system RC346-429 Jiao L Huang X Fan C Zhao H Li Z Shen H Chen J Duan J Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia
description	Lidong Jiao,1 Xiaoqin Huang,1 Chunqiu Fan,1 Hong Zhao,2 Zhen Li,3 Huixin Shen,1 Jian Chen,4 Jiangang Duan5 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China; 2Department of Hematology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China; 3Department of Ophthalmology, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China; 4Department of Neurosurgery, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of China; 5Department of Emergency, Xuanwu Hospital, Capital Medical University, Beijing, People’s Republic of ChinaCorrespondence: Xiaoqin HuangDepartment of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People’s Republic of ChinaTel +86 10-83198899– 8319Email huangxqxw@126.comBackground and Objective: Essential thrombocythemia (ET) is a rare cause of cerebral venous sinus thrombosis (CVST). Analysis of the risk factors and treatment therapies of CVST in ET has yielded controversial findings.Subjects and Methods: We retrospectively investigated the clinical characteristics of CVST events in ET and compared baseline characteristics, causative factors, hematological effects, and treatments between ET patients with and without CVST.Results: Overall, 91 of 115 patients who met the ET diagnosis were included in this study. Among them, 23 (25.27%) patients met the diagnostic criteria of ET with CVST for inclusion, 14 (60.87%) of whom were females, with a median age of 34 (range 25– 50). CVST diagnosis was made concomitantly to ET in 19 patients (82.61%). The most common symptom and sites of thrombosis of CVST was an acute or subacute headache and sigmoid sinuses, respectively. Compared with ET patients without CVST, ET patients with CVST were significantly younger (37.65± 14.45 vs 60.93± 13.46, P< 0.001) and had lower prevalence of hypertension (4.34 vs 32.35%, P=0.003) and coronary artery disease (0 vs 14.71%, P = 0.045). Patients with CVST presented with signiﬁcant lower platelet count (510.39± 176.71 vs 750.82± 249.10, P< 0.001) and higher score of IPSET-thrombosis (P=0.017). Multivariate logistic regression analysis indicated that age (P=0.002, OR 1.096, 95% CI 1.035– 1.161), at least one CVRF (P = 0.024, OR 0.037, 95% CI 0.002– 0.649), platelet count (P=0.045, OR 0.994, 95% CI 0.989– 1.001), and lower percentage of antiplatelet therapy (P=0.035, OR 0.307, 95% CI 0.001-1.280) significantly contributed to the risk of CVST in ET.Conclusion: Most patients (95.65%) had a favorable outcome without recurrence after standard anticoagulant and cytoreductive treatment at last follow-up. These findings indicate that CVST may be the initial presentation of ET, with its detection crucial for early diagnosis and appropriate management. Anticoagulant and cytoreductive therapies should be recommended for preventing ET-related CVST with JAK2 V617F mutation.Keywords: cerebral venous thrombosis, JAK2 V617F, anticoagulant therapy, cytoreductive therapy, essential thrombocythemia
format	article
author	Jiao L Huang X Fan C Zhao H Li Z Shen H Chen J Duan J
author_facet	Jiao L Huang X Fan C Zhao H Li Z Shen H Chen J Duan J
author_sort	Jiao L
title	Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia
title_short	Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia
title_full	Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia
title_fullStr	Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia
title_full_unstemmed	Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia
title_sort	clinical characteristics and management of cerebral venous sinus thrombosis in patients with essential thrombocythemia
publisher	Dove Medical Press
publishDate	2021
url	https://doaj.org/article/d02231c1052e42b097b0a9fe655961c7
work_keys_str_mv	AT jiaol clinicalcharacteristicsandmanagementofcerebralvenoussinusthrombosisinpatientswithessentialthrombocythemia AT huangx clinicalcharacteristicsandmanagementofcerebralvenoussinusthrombosisinpatientswithessentialthrombocythemia AT fanc clinicalcharacteristicsandmanagementofcerebralvenoussinusthrombosisinpatientswithessentialthrombocythemia AT zhaoh clinicalcharacteristicsandmanagementofcerebralvenoussinusthrombosisinpatientswithessentialthrombocythemia AT liz clinicalcharacteristicsandmanagementofcerebralvenoussinusthrombosisinpatientswithessentialthrombocythemia AT shenh clinicalcharacteristicsandmanagementofcerebralvenoussinusthrombosisinpatientswithessentialthrombocythemia AT chenj clinicalcharacteristicsandmanagementofcerebralvenoussinusthrombosisinpatientswithessentialthrombocythemia AT duanj clinicalcharacteristicsandmanagementofcerebralvenoussinusthrombosisinpatientswithessentialthrombocythemia
_version_	1718380398656880640

Clinical Characteristics and Management of Cerebral Venous Sinus Thrombosis in Patients with Essential Thrombocythemia

Ejemplares similares